Septerna (NASDAQ:SEPN) Receives “Overweight” Rating from Cantor Fitzgerald

Septerna (NASDAQ:SEPN)‘s stock had its “overweight” rating reiterated by research analysts at Cantor Fitzgerald in a research note issued on Tuesday,Benzinga reports. They currently have a $50.00 price objective on the stock. Cantor Fitzgerald’s price target would suggest a potential upside of 341.70% from the stock’s current price.

Several other brokerages also recently weighed in on SEPN. TD Cowen began coverage on shares of Septerna in a research note on Tuesday, November 19th. They issued a “buy” rating on the stock. Wells Fargo & Company began coverage on shares of Septerna in a research note on Tuesday, November 19th. They issued an “overweight” rating and a $43.00 target price on the stock. Finally, JPMorgan Chase & Co. began coverage on shares of Septerna in a research note on Tuesday, November 19th. They issued an “overweight” rating and a $38.00 target price on the stock.

Septerna Trading Down 0.5 %

Septerna stock opened at $11.32 on Tuesday. The company’s fifty day simple moving average is $19.87. Septerna has a 52-week low of $10.34 and a 52-week high of $28.99.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the stock. New York State Common Retirement Fund purchased a new position in Septerna in the 4th quarter worth about $32,000. PNC Financial Services Group Inc. purchased a new position in Septerna in the 4th quarter worth about $61,000. SG Americas Securities LLC purchased a new position in Septerna in the 4th quarter worth about $185,000. Corebridge Financial Inc. purchased a new position in Septerna in the 4th quarter worth about $212,000. Finally, M&T Bank Corp purchased a new position in Septerna in the 4th quarter worth about $376,000.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.